#1 Clinical Trials Search in Europe

Glutamate Decarboxylase 2, Human, Recombinant

Recent clinical trials are investigating the use of Glutamate Decarboxylase 2 (GAD2), a human recombinant protein, as a potential treatment for Type 1 Diabetes (T1D) and Latent Autoimmune Diabetes in Adults (LADA). These studies focus on preserving beta cell function, improving glycemic control, and potentially slowing disease progression in individuals with specific genetic markers. The trials involve intralymphatic injections of Diamyd, a suspension containing GAD2, and aim to evaluate its safety, efficacy, and impact on the immune system in various patient populations.

Table of Contents

What is Diamyd?

Diamyd is an investigational drug being developed to treat type 1 diabetes (T1D) and Latent Autoimmune Diabetes in Adults (LADA). Its active ingredient is glutamate decarboxylase 2 (GAD65), a human protein produced through recombinant DNA technology[1]. Diamyd is manufactured by Diamyd Medical AB and is currently being studied in clinical trials to evaluate its safety and effectiveness[2].

How Does Diamyd Work?

Diamyd aims to preserve the body’s ability to produce insulin by targeting the autoimmune process in type 1 diabetes. In T1D and LADA, the immune system mistakenly attacks and destroys insulin-producing beta cells in the pancreas. Diamyd contains GAD65, a protein found in these beta cells, and is designed to “retrain” the immune system to stop attacking them[1].

By preserving beta cell function, the goal is to maintain the body’s natural insulin production, potentially slowing disease progression and improving blood sugar control[2].

What Conditions Does Diamyd Treat?

Diamyd is being investigated for the treatment of:

  • Type 1 Diabetes (T1D): An autoimmune condition where the body’s immune system attacks and destroys insulin-producing cells in the pancreas[2].
  • Latent Autoimmune Diabetes in Adults (LADA): A slow-progressing form of autoimmune diabetes that occurs in adults, sometimes called “type 1.5 diabetes”[1].

Diamyd is being studied in people who have been recently diagnosed with T1D or LADA, as well as in individuals who are at risk of developing T1D but have not yet been diagnosed[3].

How is Diamyd Administered?

Diamyd is given as an intralymphatic injection. This means it is injected directly into a lymph node, typically in the groin area[1][2]. This method of administration is chosen to potentially enhance the immune-modulating effects of the treatment.

The treatment regimen typically involves multiple doses given over several months, with the exact schedule varying depending on the specific clinical trial protocol[2].

Current Clinical Trials

Diamyd is currently being studied in several clinical trials:

  1. A Phase III trial for adolescents and adults (ages 12-28) with recently diagnosed T1D who carry specific genetic markers (HLA DR3-DQ2)[2].
  2. A Phase II trial for children and adolescents (ages 8-17) who are at risk of developing T1D but have not yet been diagnosed[3].
  3. A follow-up study on LADA patients to evaluate the long-term effects of Diamyd treatment[1].

Potential Benefits of Diamyd

If successful, Diamyd could offer several potential benefits for people with T1D or LADA:

  • Preservation of beta cell function, potentially slowing disease progression[2].
  • Improved blood sugar control and reduced HbA1c levels[2].
  • Reduced insulin requirements[2].
  • Possible delay or prevention of T1D in high-risk individuals[3].

Safety Considerations

As with any investigational treatment, the safety of Diamyd is being closely monitored in clinical trials. Some important safety considerations include:

  • Potential injection site reactions[2].
  • Possible immune system effects, which are being carefully studied[2][3].
  • The need to avoid certain vaccines around the time of Diamyd treatment[2].
  • Contraindications for people with certain medical conditions or taking specific medications[2][3].

It’s important to note that as an investigational treatment, Diamyd is not yet approved for general use. Patients interested in this treatment should discuss clinical trial opportunities with their healthcare providers.

Aspect Details
Drug Name Diamyd (Glutamate Decarboxylase 2, Human, Recombinant)
Administration Method Intralymphatic injection
Target Conditions Type 1 Diabetes (T1D), Latent Autoimmune Diabetes in Adults (LADA), At-risk individuals
Key Inclusion Criteria HLA DR3-DQ2 haplotype, specific age ranges, presence of certain autoantibodies
Primary Objectives Evaluate safety, efficacy in preserving beta cell function, impact on glycemic control
Secondary Objectives Assess effects on immune system, diabetes progression, and metabolic status
Trial Phases Phase II and Phase III
Key Measurements C-peptide levels, HbA1c, insulin secretion, autoantibody levels
Safety Monitoring Adverse events, injection site reactions, physical examinations, vital signs, laboratory tests

FAQ

  • What is Glutamate Decarboxylase 2 (GAD2) and how is it being used in these clinical trials? Glutamate Decarboxylase 2 (GAD2) is a human recombinant protein being studied as a potential treatment for Type 1 Diabetes and LADA. In these trials, it's administered as Diamyd, a suspension for injection, given intralymphatically (into lymph nodes) to preserve beta cell function and improve glycemic control in patients with specific genetic markers.
  • Who are the target participants for these clinical trials? The trials target different groups: one focuses on LADA patients, another on adolescents and adults (12-29 years) with recently diagnosed T1D, and a third on individuals aged 8-17 at risk for T1D. All trials require participants to have specific genetic markers, particularly the HLA DR3-DQ2 haplotype, and most require the presence of certain autoantibodies.
  • What are the main objectives of these clinical trials? The main objectives vary slightly between trials but generally include: evaluating the safety and efficacy of Diamyd in preserving beta cell function, assessing its impact on glycemic control, studying its effects on the immune system, and investigating its potential to slow or prevent the progression of diabetes in at-risk individuals.
  • How is the drug administered in these trials? The drug Diamyd, containing Glutamate Decarboxylase 2, is administered via intralymphatic injection. This means it's injected directly into lymph nodes, typically in the inguinal (groin) area. The number of injections and the time between them vary among the trials, ranging from two to three injections given about a month apart.
  • What are some of the key inclusion and exclusion criteria for these trials? Key inclusion criteria often include specific age ranges, presence of the HLA DR3-DQ2 genetic marker, and certain autoantibodies. Exclusion criteria typically include diagnosis of other significant medical conditions, recent vaccinations, pregnancy or breastfeeding, and use of immunosuppressive medications. The exact criteria vary between trials, so it's important to check the specific requirements for each study.

Ongoing Clinical Trials on Glutamate Decarboxylase 2, Human, Recombinant

  • Study on Latent Autoimmune Diabetes in Adults (LADA) Patients: Evaluating Diabetes Status 3 Years After Treatment with Glutamate Decarboxylase 2

    Not recruiting

    2 1 1
    Investigated drugs:
    Norway Sweden

  • Study on the Safety and Feasibility of Diamyd (Glutamate Decarboxylase 2) for Individuals Aged 8-17 at Risk for Type 1 Diabetes with HLA DR3-DQ2 Haplotype

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Sweden

  • Study on the Safety and Effectiveness of Diamyd and Colecalciferol for Adolescents and Adults with Recently Diagnosed Type 1 Diabetes

    Not recruiting

    3 1 1
    Investigated drugs:
    Czechia Estonia Germany Hungary The Netherlands Poland +2

Glossary

  • Glutamate Decarboxylase 2 (GAD2): A human recombinant protein being studied as a potential treatment for Type 1 Diabetes and LADA. It's the active substance in the investigational drug Diamyd.
  • Latent Autoimmune Diabetes in Adults (LADA): A form of diabetes that shares characteristics of both Type 1 and Type 2 diabetes, typically diagnosed in adults and progressing more slowly than classic Type 1 diabetes.
  • HLA DR3-DQ2 haplotype: A specific genetic marker associated with increased risk for Type 1 diabetes, which is used as an inclusion criterion in these clinical trials.
  • Intralymphatic injection: A method of drug administration where the medication is injected directly into lymph nodes, typically in the inguinal (groin) area.
  • Beta cell function: The ability of beta cells in the pancreas to produce and secrete insulin. Preserving this function is a key goal in diabetes treatment.
  • Glycemic control: The management of blood sugar levels in individuals with diabetes, often measured by HbA1c levels.
  • Autoantibodies: Antibodies produced by the immune system that target the body's own tissues. In Type 1 diabetes, these include antibodies against GAD65, IA-2, ZnT8, and insulin.
  • HbA1c: A measure of average blood sugar levels over the past 2-3 months, used to assess long-term glycemic control.
  • C-peptide: A substance produced along with insulin by the pancreas, used as a marker of insulin production and beta cell function.
  • Diamyd: The brand name of the investigational drug containing Glutamate Decarboxylase 2, administered as a suspension for injection in these clinical trials.

References

  1. http://clinicaltrials.eu/trial/study-on-latent-autoimmune-diabetes-in-adults-lada-patients-evaluating-diabetes-status-3-years-after-treatment-with-glutamate-decarboxylase-2/
  2. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-diamyd-and-colecalciferol-for-adolescents-and-adults-with-recently-diagnosed-type-1-diabetes/
  3. http://clinicaltrials.eu/trial/study-on-the-safety-and-feasibility-of-diamyd-glutamate-decarboxylase-2-for-individuals-aged-8-17-at-risk-for-type-1-diabetes-with-hla-dr3-dq2-haplotype/